focus -WSS

focus

author：Wikipedia 2025-09-27 22:18:12 - browse：616

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Trump seeks lengthy delay of classified docs trial, citing upcoming election

explore

entertainment

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

CZI to create biohub to build anti

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

How redistricting in 6 states could affect who controls Congress

Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

focus

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth, Optum discontinue NaviHealth name

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Supreme Court strikes down use of affirmative action

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Moonlake's readout produced a cash windfall. Risks remain

How AI can help patients find reliable information about doctors

hotspot

California man arrested in connection with serial murders of Mexican strip club workers

Health tech investors get more selective as pandemic boom fades

How AI can help patients find reliable information about doctors

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Why a market frenzy over new weight loss drugs defies logic

STAT Summit: The economic case for universal basic health care

leisure time

explore

entertainment

hotspot